27652718|t|Randomized Trial of Long-Acting Insulin Glargine Titration Web Tool (LTHome) Versus Enhanced Usual Therapy of Glargine Titration (INNOVATE Trial)
27652718|a|Basal insulin titration in the real world is often unsuccessful. LTHome, a web tool, applies a rules engine-based algorithm providing insulin titration advice directly to the patient. This pilot, randomized trial evaluates basal insulin glargine titration by LTHome compared to enhanced usual therapy ([EUT]- diabetes education program) over 12 weeks. Important inclusion criteria: 18-75 years, type 2 diabetes, computer literacy, and HbA1c >7.0%. Trial protocol was approved by ethics board. We randomized 139 subjects. The achievement of primary composite outcome (four out of seven fasting plasma glucose [FPG] within 5-7.2 mmol/L + mean for three consecutive FPG within 5-7.2 mmol/L + no severe hypoglycemia) was 15% in LTHome versus 41% in EUT (noninferiority not met, P-value = 0.92). Other outcomes were similar between the LTHome and EUT arms: alternate composite outcome achievement (last five FPG mean within the range of 5-7.2 mmol/L + no hypoglycemia, 47% and 51%, P = 0.73); A1c reduction (-1.0% and -1.1%, P = 0.66); proportion achieving A1c â‰¤7% (14% and 20%, P = 0.36); and hypoglycemia incidence (31% and 37%, P = 0.4), respectively. Patient satisfaction score improvements were greater in LTHome versus EUT (change in fear of hypoglycemia score P = 0.04 and change in diabetes distress score P = 0.04). The mean number of additional healthcare provider visits was 0.13 for LTHome and 1.22 for EUT (P < 0.01). INNOVATE trial suggests clinical utility of LTHome compared to EUT in real-life settings. Further research is needed to evaluate the efficacy and safety of automated insulin titration algorithms.
27652718	0	16	Randomized Trial	T062,T170	C0206034
27652718	20	39	Long-Acting Insulin	T116,T121,T125	C0304870
27652718	40	48	Glargine	T116,T121,T125	C0907402
27652718	49	58	Titration	T059	C0162621
27652718	59	67	Web Tool	T170	C0037589
27652718	69	75	LTHome	T170	C0037589
27652718	84	92	Enhanced	T052	C2349975
27652718	93	98	Usual	T080	C3538928
27652718	99	106	Therapy	T061	C0087111
27652718	110	118	Glargine	T116,T121,T125	C0907402
27652718	119	128	Titration	T059	C0162621
27652718	130	144	INNOVATE Trial	T062	C0008976
27652718	146	159	Basal insulin	T116,T121	C0650607
27652718	160	169	titration	T059	C0162621
27652718	197	209	unsuccessful	T080	C1272705
27652718	211	217	LTHome	T170	C0037589
27652718	221	229	web tool	T170	C0037589
27652718	231	238	applies	T169	C4048755
27652718	241	246	rules	T170	C0870077
27652718	247	269	engine-based algorithm	T170	C0002045
27652718	280	287	insulin	T116,T121,T125	C0021641
27652718	288	297	titration	T059	C0162621
27652718	321	328	patient	T101	C0030705
27652718	342	358	randomized trial	T062,T170	C0206034
27652718	359	368	evaluates	T058	C0220825
27652718	369	382	basal insulin	T116,T121	C0650607
27652718	383	391	glargine	T116,T121,T125	C0907402
27652718	392	401	titration	T059	C0162621
27652718	405	411	LTHome	T170	C0037589
27652718	424	432	enhanced	T052	C2349975
27652718	433	438	usual	T080	C3538928
27652718	439	446	therapy	T061	C0087111
27652718	449	452	EUT	T061	C0087111
27652718	455	481	diabetes education program	T058	C1532353
27652718	491	496	weeks	T079	C0439230
27652718	508	517	inclusion	T080	C1512693
27652718	518	526	criteria	T078	C0243161
27652718	541	556	type 2 diabetes	T047	C0011860
27652718	558	575	computer literacy	T041	C0009603
27652718	581	586	HbA1c	T116,T123	C0019018
27652718	594	599	Trial	T062	C0008976
27652718	600	608	protocol	T170	C1507394
27652718	642	652	randomized	T062	C0034656
27652718	657	665	subjects	T098	C0080105
27652718	671	682	achievement	T053	C0001072
27652718	686	693	primary	T080	C0205225
27652718	694	703	composite	T080	C0205199
27652718	704	711	outcome	T080	C0085415
27652718	731	759	fasting plasma glucose [FPG]	T034	C1318375
27652718	782	786	mean	T081	C0444504
27652718	797	808	consecutive	T080	C1707491
27652718	809	812	FPG	T034	C1318375
27652718	835	837	no	T033	C1513916
27652718	838	844	severe	T080	C0205082
27652718	845	857	hypoglycemia	T047	C0020615
27652718	870	876	LTHome	T170	C0037589
27652718	891	894	EUT	T061	C0087111
27652718	920	927	P-value	T081	C1709380
27652718	943	951	outcomes	T080	C0085415
27652718	977	983	LTHome	T170	C0037589
27652718	988	991	EUT	T061	C0087111
27652718	1008	1017	composite	T080	C0205199
27652718	1018	1025	outcome	T080	C0085415
27652718	1026	1037	achievement	T053	C0001072
27652718	1049	1052	FPG	T034	C1318375
27652718	1053	1057	mean	T081	C0444504
27652718	1093	1095	no	T033	C1513916
27652718	1096	1108	hypoglycemia	T047	C0020615
27652718	1123	1124	P	T081	C1709380
27652718	1134	1137	A1c	T116,T123	C0019018
27652718	1138	1147	reduction	T080	C0392756
27652718	1166	1167	P	T081	C1709380
27652718	1177	1187	proportion	T081	C1709707
27652718	1198	1201	A1c	T116,T123	C0019018
27652718	1220	1221	P	T081	C1709380
27652718	1235	1247	hypoglycemia	T047	C0020615
27652718	1248	1257	incidence	T081	C0021149
27652718	1272	1273	P	T081	C1709380
27652718	1296	1303	Patient	T101	C0030705
27652718	1317	1322	score	T081	C0449820
27652718	1341	1348	greater	T081	C1704243
27652718	1352	1358	LTHome	T170	C0037589
27652718	1366	1369	EUT	T061	C0087111
27652718	1371	1377	change	T169	C0392747
27652718	1381	1385	fear	T041	C0015726
27652718	1389	1401	hypoglycemia	T047	C0020615
27652718	1402	1407	score	T081	C0449820
27652718	1408	1409	P	T081	C1709380
27652718	1421	1427	change	T169	C0392747
27652718	1431	1439	diabetes	T047	C0011847
27652718	1440	1448	distress	T033	C0231303
27652718	1449	1454	score	T081	C0449820
27652718	1455	1456	P	T081	C1709380
27652718	1470	1474	mean	T081	C0444504
27652718	1496	1506	healthcare	T058	C0086388
27652718	1507	1515	provider	T169	C1138603
27652718	1516	1522	visits	T058	C1512346
27652718	1536	1542	LTHome	T170	C0037589
27652718	1556	1559	EUT	T061	C0087111
27652718	1561	1562	P	T081	C1709380
27652718	1572	1586	INNOVATE trial	T062	C0008976
27652718	1596	1604	clinical	T080	C0205210
27652718	1605	1612	utility	T169	C0457083
27652718	1616	1622	LTHome	T170	C0037589
27652718	1635	1638	EUT	T061	C0087111
27652718	1642	1660	real-life settings	T080	C0205556
27652718	1670	1678	research	T062	C0035168
27652718	1692	1700	evaluate	T058	C0220825
27652718	1705	1713	efficacy	T080	C1280519
27652718	1718	1724	safety	T068	C0036043
27652718	1728	1737	automated	T169	C0205554
27652718	1738	1745	insulin	T116,T121,T125	C0021641
27652718	1746	1755	titration	T059	C0162621
27652718	1756	1766	algorithms	T170	C0002045